Expression of glycosaminoglycans in cirrhotic liver and hepatocellular carcinoma-a pilot study including etiology

Anal Bioanal Chem. 2022 May;414(13):3837-3846. doi: 10.1007/s00216-022-04025-3. Epub 2022 Mar 28.

Abstract

Chronic liver diseases have both high incidence and mortality rates; therefore, a deeper understanding of the underlying molecular mechanisms is essential. We have determined the content and sulfation pattern of chondroitin sulfate (CS) and heparan sulfate (HS) in human hepatocellular carcinoma and cirrhotic liver tissues, considering the etiology of the diseases. A variety of pathological conditions such as alcoholic liver disease, hepatitis B and C virus infections, and primary sclerosing cholangitis were studied. Major differences were observed in the total abundance and sulfation pattern of CS and HS chains. For example, the 6-O-sulfation of CS is fundamentally different regarding etiologies of cirrhosis, and a 2-threefold increase in HS N-sulfation/O-sulfation ratio was observed in hepatocellular carcinoma compared to cirrhotic tissues.

Keywords: Chondroitin sulfate; Cirrhosis; Glycosaminoglycan; Heparan sulfate; Hepatocellular carcinoma; Liver cancer.

MeSH terms

  • Carcinoma, Hepatocellular*
  • Chondroitin Sulfates
  • Glycosaminoglycans / metabolism
  • Heparan Sulfate
  • Humans
  • Liver Cirrhosis
  • Liver Neoplasms*
  • Pilot Projects

Substances

  • Chondroitin Sulfates
  • Glycosaminoglycans
  • Heparan Sulfate